Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters

Bag, Asim K.; Cezayirli, Phillip; Davenport, Jake J.; Gaddikeri, Santhosh; Fathallah‐Shaykh, Hassan M.; Cantor, Alan; Han, Xiaosi; Nabors, L. Burt

doi:10.1007/s11060-014-1560-9

Cited by 20 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased DSC-CBV was found to be predictive of decreased progression free survival [ 20 , 116 , 117 , 118 , 119 , 125 , 126 , 127 ] and decreased OS [ 20 , 71 , 117 , 119 , 122 , 123 , 124 , 125 , 128 , 129 , 130 , 130 , 131 , 132 , 133 , 134 ] in diffuse cerebral gliomas. These parameters can be also used to follow-up on lower grade glioma lesions and to monitor treatment effects [ 122 , 135 , 136 ]. An increase in DSC-CBV during follow up of low-grade gliomas has, for example, been suggested to predict malignant transformation [ 137 ].…”

Section: Clinical Applications Of Hemodynamic Imaging In Gliomas—partmentioning

confidence: 99%

Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions

Stumpo

Guida

Bellomo

et al. 2022

Cancers

View full text Add to dashboard Cite

Gliomas, and glioblastoma in particular, exhibit an extensive intra- and inter-tumoral molecular heterogeneity which represents complex biological features correlating to the efficacy of treatment response and survival. From a neuroimaging point of view, these specific molecular and histopathological features may be used to yield imaging biomarkers as surrogates for distinct tumor genotypes and phenotypes. The development of comprehensive glioma imaging markers has potential for improved glioma characterization that would assist in the clinical work-up of preoperative treatment planning and treatment effect monitoring. In particular, the differentiation of tumor recurrence or true progression from pseudoprogression, pseudoresponse, and radiation-induced necrosis can still not reliably be made through standard neuroimaging only. Given the abundant vascular and hemodynamic alterations present in diffuse glioma, advanced hemodynamic imaging approaches constitute an attractive area of clinical imaging development. In this context, the inclusion of objective measurable glioma imaging features may have the potential to enhance the individualized care of diffuse glioma patients, better informing of standard-of-care treatment efficacy and of novel therapies, such as the immunotherapies that are currently increasingly investigated. In Part B of this two-review series, we assess the available evidence pertaining to hemodynamic imaging for molecular feature prediction, in particular focusing on isocitrate dehydrogenase (IDH) mutation status, MGMT promoter methylation, 1p19q codeletion, and EGFR alterations. The results for the differentiation of tumor progression/recurrence from treatment effects have also been the focus of active research and are presented together with the prognostic correlations identified by advanced hemodynamic imaging studies. Finally, the state-of-the-art concepts and advancements of hemodynamic imaging modalities are reviewed together with the advantages derived from the implementation of radiomics and machine learning analyses pipelines.

show abstract

Section: Clinical Applications Of Hemodynamic Imaging In Gliomas—partmentioning

confidence: 99%

Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions

Stumpo

Guida

Bellomo

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Some studies have focused on the perfusion characteristics of nonenhancing T2 high-signal-intensity lesions in glioblastoma to predict prognosis. [14][15][16] However, there have been few investigations of the DCE-MR imaging-derived pharmacokinetic parameters of nonenhancing T2 high-signal-intensity lesions of glioblastoma at the time of baseline and post concurrent chemoradiation therapy (CCRT) and their temporal change.…”

Section: Discussionmentioning

confidence: 99%

Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value

Hwang¹,

Choi²,

Ck³

et al. 2019

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE: The prognostic value of dynamic contrast-enhanced MR imaging on nonenhancing T2 high-signal-intensity lesions in patients with glioblastoma has not been thoroughly elucidated to date. We evaluated the temporal change and prognostic value for progression-free survival of dynamic contrast-enhanced MR imaging-derived pharmacokinetic parameters on nonenhancing T2 high-signal-intensity lesions in patients with glioblastoma before and after standard treatment, including gross total surgical resection.

show abstract

“…According to Bonekamp et al (38), preoperative perfusion MRI showed that an elevated CBV value was associated with worse overall survival. Interestingly, Bag et al (22) demonstrated that there was a statistically significant association between posttreatment perfusion parameters and overall survival (OS), but that there was no such association between pre-treatment perfusion parameters and OS. In our study, multivariable linear regression even confirmed that surgical extent and 1p/19q deletion are the only meaningful prognostic factors for glioblastoma overall survival.…”

Section: A B Cmentioning

confidence: 99%

“…Additionally, by using perfusion dynamic susceptibility contrast (DSC) MRI, differential diagnosis between glioblastoma and primary central nervous system (CNS) lymphoma can be achieved with a high diagnostic confidence (20). While perfusion DSC-MRI has shown a strong correlation between glioma grade and rCBV values (21), the relationships between DSC perfusion parameters and genetic markers/overall survival are not straightforward (22,23). Beyond MRI, clinical factors, such as the extent of resection, are regarded as important prognostic factors for GBM (24).…”

Section: Introductionmentioning

confidence: 99%

Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions

Kwon

Moon

Park

et al. 2018

Investig Magn Reson Imaging

View full text Add to dashboard Cite

To investigate the surgical, perfusion, and molecular characteristics of glioblastomas which influence long-term survival after treatment, and to explore the association between MR perfusion parameters and the presence of MGMT methylation and 1p/19q deletions. Materials and Methods: This retrospective study was approved by our institutional review board. A total 43 patients were included, all with pathologic diagnosis of glioblastoma with known MGMT methylation and 1p/19q deletion statuses. We divided these patients into longterm (≥ 60 months, n = 7) and short-term (< 60 months, n = 36) survivors, then compared surgical extent, molecular status, and rCBV parameters between the two groups using Fisher's exact test or Mann-Whitney test. The rCBV parameters were analyzed according to the presence of MGMT methylation and 1p/19q deletions. We investigated the relationship between the mean rCBV and overall survival using linear correlation. Multivariable linear regression was performed in order to find the variables related to overall survival. Results: Long-term survivors (100% [7 of 7]) demonstrated a greater percentage of gross total or near total resection than short-term survivors (54.5% [18 of 33]). A higher prevalence of 1p/19q deletions was also noted among the long-term survivors (42.9% [3 of 7]) than the short-term survivors (0.0% [0 of 36]). The rCBV parameters did not differ between the longterm and short-term survivors. The rCBV values were marginally lower in patients with MGMT methylation and 1p/19q deletions. Despite no correlation found between overall survival and rCBV in the whole group, the short-term survivor group showed negative correlation (R 2 = 0.181, P = 0.025). Multivariable linear regression revealed that surgical extent and 1p/19q deletions, but not rCBV values, were associated with prolonged overall survival. Conclusion: While preoperative rCBV and 1p/19q deletion status are related to each other, only surgical extent and the presence of 1p/19q deletion in GBM patients may predict longterm survival.

show abstract

Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters

Cited by 20 publications

References 34 publications

Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions

Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions

Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value

Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions

Contact Info

Product

Resources

About